Citadel Advisors’s Phio Pharmaceuticals PHIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $48.3K | Buy |
+47,150
| New | +$53.7K | ﹤0.01% | 13129 |
|
|
2025
Q1 | – | Sell |
-44,526
| Closed | -$80.1K | – | 15321 |
|
|
2024
Q4 | $80.1K | Buy |
+44,526
| New | +$121K | ﹤0.01% | 11779 |
|
|
2024
Q3 | – | Sell |
-2,410
| Closed | -$15.2K | – | 14975 |
|
|
2024
Q2 | $15.2K | Buy |
+2,410
| New | +$15.8K | ﹤0.01% | 12848 |
|
|
2024
Q1 | – | Sell |
-3,538
| Closed | -$24.2K | – | 15262 |
|
|
2023
Q4 | $24.2K | Buy |
+3,538
| New | +$36.4K | ﹤0.01% | 12458 |
|
|
2022
Q1 | – | Sell |
-269
| Closed | -$29K | – | 14339 |
|
|
2021
Q4 | $29K | Buy |
269
+18
| +7% | +$2.86K | ﹤0.01% | 13488 |
|
|
2021
Q3 | $55K | Sell |
251
-92
| -27% | -$19.2K | ﹤0.01% | 13319 |
|
|
2021
Q2 | $84K | Buy |
343
+128
| +60% | +$31.6K | ﹤0.01% | 13046 |
|
|
2021
Q1 | $62K | Buy |
+215
| New | +$71.5K | ﹤0.01% | 12794 |
|
|
2020
Q4 | – | Sell |
-113
| Closed | -$26K | – | 11375 |
|
|
2020
Q3 | $26K | Buy |
+113
| New | +$28.8K | ﹤0.01% | 9802 |
|
|
2019
Q3 | – | Sell |
-14
| Closed | -$33K | – | 9616 |
|
|
2019
Q2 | $33K | Buy |
14
+8
| +133% | +$21K | ﹤0.01% | 8846 |
|
|
2019
Q1 | $15K | Buy |
6
+3
| +100% | +$6.73K | ﹤0.01% | 9111 |
|
|
2018
Q4 | $7K | Buy |
+3
| New | +$7.09K | ﹤0.01% | 8968 |
|
|
2018
Q1 | – | Hold |
0
| – | -$16K | – | 8656 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7864 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | -$34.5K | – | 7450 |
|
|
2017
Q2 | $28K | Buy |
+1
| New | +$37K | ﹤0.01% | 7223 |
|
|
2016
Q4 | – | Hold |
0
| – | -$22K | – | 7695 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 7022 |
|
|
2016
Q2 | – | Hold |
0
| – | -$25K | – | 7253 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6416 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 8005 |
|
|
2015
Q1 | – | Hold |
0
| – | -$19K | – | 8770 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 7850 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 7276 |
|
|
2014
Q2 | – | Hold |
0
| – | -$53K | – | 8215 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 6743 |
|
Other funds holding PHIO
NAMI
XT
HF
Citadel Advisors's PHIO Position: Q2 2026 in Review
Citadel Advisors opened a new position in Phio Pharmaceuticals (PHIO) in Q2 2026: 47,150 shares worth $48.3K. The stake represents ﹤0.01% of the portfolio and ranks #13129 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PHIO as recently as Q4 2024.
Citadel Advisors first reported a position in PHIO in Q2 2017 and has held it in 13 quarters since. The position peaked at $84K in Q2 2021. 24 funds tracked by Wall St. Rank hold PHIO as of Q2 2026.
- Citadel Advisors held 47,150 shares of Phio Pharmaceuticals worth $48.3K as of Q2 2026.
- Phio Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
- Phio Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13129 holding.
- Citadel Advisors first reported a position in Phio Pharmaceuticals in Q2 2017 and has held it in 13 quarters since.
- Citadel Advisors's Phio Pharmaceuticals position peaked at $84K in Q2 2021.
- 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.